A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

@article{Pan2012APP,
  title={A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma},
  author={Edward A. Pan and Daohai Yu and Binglin Yue and Lisa Potthast and Sajeel A. Chowdhary and Pamela P Smith and Marc Chamberlain},
  journal={Journal of Neuro-Oncology},
  year={2012},
  volume={110},
  pages={111-118}
}
Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors, was evaluated for treatment of patients with recurrent glioblastoma (GB) and anaplastic astrocytoma (AA). Fourteen AA and 16 GB patients, all previously treated with surgery, radiotherapy, and temozolomide, were enrolled in a prospective phase II study at either… CONTINUE READING